The experiment followed exposure over time
Airhart and colleagues studied eight healthy volunteers in a non-randomized, open-label pharmacokinetic experiment. NR was increased over several days, followed by twenty-four-hour blood sampling on day nine. Circulating NR and NAD increased relative to baseline; average steady-state NAD was approximately twice the baseline level. No adverse events were reported. [1]
The study’s objectives concerned pharmacokinetics and whole-blood NAD. It did not test whether NR improved heart-failure outcomes, exercise performance or everyday energy. Discussion of potential future therapeutic use should be read as a rationale for later trials. [1]
What a concentration-time study can explain
Pharmacokinetic work asks how measured exposure changes with time under a specified regimen. That can help investigators decide when to sample, how to design another experiment and which measurements are practical. It does not require a claim of clinical benefit to be worthwhile.
The schedule is nevertheless part of the result. A measurement after several days of escalating exposure is not the same as a result after one ordinary retail serving. A product summary should not remove the preceding regimen and present the day-nine observation as an immediate consumer expectation.
This is also why a single peak concentration is not a complete comparison of products. A fair pharmacology comparison would need a clearly specified measure and consistent sampling conditions, rather than whichever time point produces the largest-looking number.
Eight volunteers cannot establish a universal response
An open-label study without a randomized control group provides a narrower basis for inference than a controlled efficacy trial. It can describe observed exposure, but it cannot answer every reason a participant might feel different or every source of variation between people.
The absence of reported adverse events is a short-term observation in eight selected people. It should not be turned into a lifetime safety statement. The research amounts are not instructions to reproduce the protocol without its clinical context.
Compare this paper with the eight-week controlled NR study, which examined sustained exposure and tolerability in a different design. Those studies can complement each other while answering different questions.
For a consumer, the useful conclusion is that oral NR influenced circulating measurements under the tested conditions. Our format explorer can match a product to oral NR, but it cannot infer better health from a concentration curve. Keep the pharmacokinetic question beside the clinical question you actually care about, and ask for evidence that addresses each rather than allowing one to stand in for the other. Timing information is most useful when the full preceding exposure and sampling schedule remain available to the reader.